Dr. De Nicolo received her M.D. from the University of Bari and her Ph.D. in Oncology and Surgical Oncology from the University of Padua. Then, she moved to Boston, MA, USA, where she trained as a Research Fellow in Genetics at Harvard Medical School and Dana-Farber Cancer Institute (Prof. David M. Livingston) and subsequently held a Faculty position (Instructor in Medicine) at Harvard Medical School, Dana-Farber Cancer Institute, and Brigham and Women’s Hospital. In Boston, Dr. De Nicolo’s research was primarily focused on elucidating the biological significance of sequence alterations in breast and/or ovarian cancer genes and gaining insights into the similarities between sporadic and hereditary, BRCA1-mutated, triple negative breast cancer. In addition, Dr. De Nicolo substantially contributed to the discovery of a novel mechanism of activation of the two major mitotic kinases, Aurora A and Plk1, and to the elucidation of a signaling cascade underlying mitotic centrosome and bipolar spindle assembly. She also participated in several collaborative projects on triple negative breast cancer, including a pilot clinical trial that tested the efficacy of neoadjuvant cisplatin. In 2016, Dr. De Nicolo joined the Veneto Institute of Oncology IRCCS with the goal of pursuing interdisciplinary translational research. Since her relocation to Italy, in addition to continuing her studies on breast/ovarian cancer predisposition, Dr. De Nicolo has expanded her scientific horizon to include research on other hereditary cancer syndromes and overlapping and atypical phenotypes. She coordinates national and international collaborative networks of centers dedicated to genetic testing for cancer predisposition, maintains collaborations with her former colleagues, and serves as a USA-Europe liaison scientist for the Scientific Directorate.